|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CN106928326B
(zh)
*
|
2015-12-31 |
2019-12-24 |
中国科学院微生物研究所 |
一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN107298712B
(zh)
*
|
2016-04-14 |
2020-04-07 |
中国疾病预防控制中心病毒病预防控制所 |
全人源化抗中东呼吸综合征冠状病毒中和抗体
|
|
TW201815821A
(zh)
*
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
KR20230041834A
(ko)
*
|
2016-08-16 |
2023-03-24 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
CN119492842A
(zh)
|
2016-10-25 |
2025-02-21 |
里珍纳龙药品有限公司 |
用于色谱数据分析的方法和系统
|
|
WO2018097603A2
(ko)
*
|
2016-11-23 |
2018-05-31 |
에스케이케미칼 주식회사 |
중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
|
|
US12016313B2
(en)
*
|
2017-01-19 |
2024-06-25 |
Omniab Operations, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
WO2018215389A1
(en)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
KR101895228B1
(ko)
|
2017-08-23 |
2018-10-30 |
대한민국 |
중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
|
|
CN118416215A
(zh)
|
2017-09-19 |
2024-08-02 |
里珍纳龙药品有限公司 |
减少粒子形成的方法以及由其形成的组合物
|
|
WO2019067671A1
(en)
*
|
2017-09-27 |
2019-04-04 |
David Weiner |
DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST
|
|
KR102017217B1
(ko)
*
|
2017-10-19 |
2019-09-02 |
주식회사 엔케이맥스 |
중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
WO2019151632A1
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
KR20190093107A
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11690907B2
(en)
|
2018-06-12 |
2023-07-04 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
US11696948B2
(en)
|
2018-06-12 |
2023-07-11 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
CN110616198B
(zh)
*
|
2018-06-19 |
2021-02-19 |
清华大学 |
一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
KR102682192B1
(ko)
*
|
2018-08-17 |
2024-07-04 |
한림대학교 산학협력단 |
메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
RU2709659C1
(ru)
*
|
2018-09-06 |
2019-12-19 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
|
|
KR102007161B1
(ko)
*
|
2018-11-07 |
2019-08-07 |
대한민국 |
메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
|
|
PL3857237T3
(pl)
|
2019-01-16 |
2023-07-10 |
Regeneron Pharmaceuticals, Inc. |
Sposoby charakteryzowania mostka disiarczkowego
|
|
WO2020169755A2
(en)
|
2019-02-20 |
2020-08-27 |
Harbour Antibodies Bv |
Antibodies
|
|
EP3934620A1
(en)
|
2019-03-05 |
2022-01-12 |
Regeneron Pharmaceuticals, Inc. |
Human serum albumin in formulations
|
|
US11364276B2
(en)
|
2019-03-26 |
2022-06-21 |
National Guard Health Affairs |
Antiviral peptides for treatment of the middle east respiratory syndrome
|
|
JP7524214B2
(ja)
*
|
2019-04-03 |
2024-07-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
|
|
KR102213745B1
(ko)
*
|
2019-04-16 |
2021-02-09 |
주식회사 바이오앱 |
돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
|
|
AU2020275406A1
(en)
|
2019-05-13 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
KR20220070262A
(ko)
*
|
2019-09-23 |
2022-05-30 |
서울대학교산학협력단 |
항-mers-cov 항체 및 이의 용도
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
EP4050035A4
(en)
*
|
2020-02-10 |
2022-12-28 |
Institute of Microbiology of Chinese Academy of Science |
Beta-coronavirus antigen, preparation method therefor and use thereof
|
|
EP4103619A1
(en)
|
2020-02-10 |
2022-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss2 antibodies and antigen-binding fragments
|
|
WO2021173753A1
(en)
|
2020-02-26 |
2021-09-02 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
CN113321713B
(zh)
*
|
2020-02-28 |
2022-11-01 |
深圳市亚辉龙生物科技股份有限公司 |
SARS-CoV-2的重组RBD蛋白及其制备方法
|
|
MX2022011142A
(es)
*
|
2020-03-09 |
2022-12-13 |
Abcellera Biologics Inc |
Anticuerpos anti-coronavirus y metodos de uso.
|
|
US20210283243A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Ibio, Inc. |
Lichenase-covid-19 based vaccine
|
|
CA3171235A1
(en)
*
|
2020-03-12 |
2021-09-16 |
Sydney David Cullis-Hill |
Treatment for coronavirus infection and associated cytokine toxicity
|
|
US11365239B2
(en)
*
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021207948A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-sars-cov-2 antibodies and uses thereof
|
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
|
JP2023521618A
(ja)
*
|
2020-04-01 |
2023-05-25 |
チオジェネシス セラピューティクス， インコーポレイテッド |
ベータコロナウイルス感染症の治療のためのシステアミン前駆体化合物
|
|
WO2021201679A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting coronaviruses
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
WO2021216876A2
(en)
*
|
2020-04-24 |
2021-10-28 |
The Board Of Regents Of The University Of Texas System |
Antibodies to coronavirus spike protein and methods of use thereof
|
|
EP4144353A4
(en)
*
|
2020-04-30 |
2024-08-28 |
FUJIFILM Toyama Chemical Co., Ltd. |
THERAPEUTIC AGENT AGAINST CORONAVIRUS INFECTION FORMED BY COMBINATION OF A PYRAZINE DERIVATIVE AND ANOTHER THERAPEUTIC DRUG AGAINST CORONAVIRUS INFECTION
|
|
GB202007532D0
(en)
*
|
2020-05-20 |
2020-07-01 |
Alchemab Therapeutics Ltd |
Polypeptides
|
|
CN116829177A
(zh)
*
|
2020-05-20 |
2023-09-29 |
纽约市哥伦比亚大学理事会 |
抗SARS-CoV-2的有效中和抗体及其生成和用途
|
|
WO2021238910A1
(en)
*
|
2020-05-25 |
2021-12-02 |
Guo Bingshi |
Anti-coronavirus spike protein antibodies and uses thereof
|
|
AU2021282179A1
(en)
|
2020-05-26 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
CN111606981B
(zh)
*
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
MX2022014852A
(es)
|
2020-06-03 |
2023-02-01 |
Regeneron Pharma |
Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
|
|
WO2021257695A2
(en)
*
|
2020-06-16 |
2021-12-23 |
Hifibio (Hk) Limited |
Methods and compositions related to neutralizing antibodies against human coronavirus
|
|
WO2021260052A1
(en)
*
|
2020-06-23 |
2021-12-30 |
Navigo Proteins Gmbh |
Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
|
|
US20250263468A1
(en)
*
|
2020-07-24 |
2025-08-21 |
Celltrion Inc. |
Binding molecule having neutralizing activity against coronavirus superfamily
|
|
WO2022026807A2
(en)
*
|
2020-07-30 |
2022-02-03 |
Albert Einstein College Of Medicine |
Antibodies targeting sars-cov-2 and uses thereof
|
|
WO2022031576A1
(en)
*
|
2020-08-03 |
2022-02-10 |
Janssen Biotech, Inc. |
Materials and methods for multidirectional biotransportation in virotherapeutics
|
|
WO2022031137A1
(ko)
*
|
2020-08-07 |
2022-02-10 |
주식회사 노블젠 |
코로나바이러스에 대한 항바이러스용 조성물
|
|
IL300828A
(en)
|
2020-08-31 |
2023-04-01 |
Regeneron Pharma |
Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
|
|
WO2022054068A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Ramot At Tel-Aviv University Ltd. |
Antibodies for the prevention, treatment and detection of coronavirus infection
|
|
US20250188154A1
(en)
*
|
2020-09-15 |
2025-06-12 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
CN116390945A
(zh)
*
|
2020-09-24 |
2023-07-04 |
博德研究所 |
无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体
|
|
CN112379087B
(zh)
*
|
2020-10-21 |
2022-02-11 |
中国医学科学院医学生物学研究所 |
一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
CN114716541B
(zh)
*
|
2021-01-05 |
2023-07-21 |
中国科学院分子细胞科学卓越创新中心 |
抗冠状病毒的全人广谱中和抗体76e1及其应用
|
|
EP4274608A4
(en)
*
|
2021-01-05 |
2025-07-09 |
Immunome Inc |
ANTIBODY COCKTAIL AGAINST SARS-CoV-2 SPIKE PROTEIN
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AU2022210469A1
(en)
*
|
2021-01-22 |
2023-07-13 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Monoclonal antibodies against corovaviruses and uses thereof
|
|
WO2022170126A2
(en)
*
|
2021-02-05 |
2022-08-11 |
Adagio Therapeutics, Inc. |
Compounds specific to coronavirus s protein and uses thereof
|
|
WO2022182662A1
(en)
|
2021-02-23 |
2022-09-01 |
10X Genomics, Inc. |
Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
|
|
EP4301784A4
(en)
*
|
2021-03-02 |
2025-01-01 |
NovaRock Biotherapeutics, Ltd. |
Antibodies against claudin-6 and uses thereof
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
US20240158478A1
(en)
*
|
2021-03-15 |
2024-05-16 |
Emory University |
SARS-CoV-2 Antibodies and Fragments, Therapeutic Uses, Diagnostic Uses, and Compositions Related Thereto
|
|
WO2022212654A2
(en)
*
|
2021-04-02 |
2022-10-06 |
The Scripps Research Institute |
Cross-reactive monoclonal antibodies against coronaviruses
|
|
WO2022241200A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Vanderbilt University |
Cross-reactive coronavirus antibodies
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
EP4370210A1
(en)
|
2021-07-14 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
JP2024528710A
(ja)
*
|
2021-07-23 |
2024-07-30 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
Ｓａｒｓ－ｃｏｖ－２、その変異株、及び関連コロナウイルスに対する強力かつ広域の中和モノクローナル抗体の特性評価ならびに使用方法
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
CN116178530A
(zh)
*
|
2021-09-26 |
2023-05-30 |
上海君实生物医药科技股份有限公司 |
抗体在治疗SARS-CoV-2感染的用途
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
JP2024538673A
(ja)
|
2021-10-07 |
2024-10-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨモデリング及び制御のシステム及び方法
|
|
WO2023244276A2
(en)
*
|
2021-10-13 |
2023-12-21 |
The Wistar Institute Of Anatomy And Biology |
DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
CN115850461A
(zh)
*
|
2022-12-06 |
2023-03-28 |
中国科学院微生物研究所 |
沙贝病毒广谱中和抗体及其应用
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
CN119264262B
(zh)
*
|
2024-09-19 |
2025-09-02 |
中山大学 |
一种双特异性抗体及其应用
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|